Artiva Biotherapeutics Shifts Focus After Clinical Trial Concerns
Following concerns surrounding patient safety, Artiva Biotherapeutics ceases its autoimmune cell therapy project and reduces workforce significantly.
Artiva Biotherapeutics is making significant changes to its operations after the unfortunate deaths of two participants in its clinical trial for an experimental cell therapy targeting autoimmune disorders. This decision comes alongside a substantial workforce reduction, with nearly 94% of the company's staff facing layoffs.
Safety Concerns Drive Decision
In a statement released on Tuesday, Artiva clarified that both deaths observed during the clinical trial do not appear to be related to their therapy, known as AlloNK. This therapy was primarily being studied for its potential benefits in treating inflammatory diseases like rheumatoid arthritis.
One patient who passed away developed leukoencephalopathy, a severe neurological condition usually linked to the chemotherapy drug fludarabine, which was administered in preparation for the AlloNK treatment. The other participant experienced sudden death about two months post-treatment, but investigators concluded that neither AlloNK nor any aspects of the treatment regimen contributed to these unfortunate outcomes.
Regulatory Response and Trial Suspension
In light of the first death, Artiva promptly notified the Food and Drug Administration (FDA), prompting the agency to request a temporary halt on the ongoing Phase 2a trial. Subsequently, the company decided to stop both the ongoing trial and enrollment for a Phase 3 trial.
Moreover, the trial results indicated that the therapeutic effects of AlloNK did not meet the expected standards of durability and clinical effectiveness that Artiva deemed necessary for further development.
Financial Implications and Future Directions
The decision to suspend the clinical work and cut staff has significant financial implications for Artiva. As of the end of September, the company reported holding $319.1 million in cash and equivalents, but the looming layoffs and halting of trials raised questions about its future. Artiva has engaged a financial advisor to undertake a strategic review, a process that could lead to asset sales or a reverse merger.
Artiva Biotherapeutics is among a cohort of firms developing cell therapies that utilize natural killer (NK) cells rather than the more commonly recognized T cells used in CAR-T therapies for cancer treatment. NK cells offer an intriguing alternative, being easier to procure and store as they can be 'off-the-shelf' therapies derived from donor cells, contrasting with personalized treatments requiring patient-specific cell collection.
A Changing Landscape
Artiva's journey through cell therapy development has seen various shifts; the company initially aimed for an initial public offering in 2022 before pivoting focus to autoimmune conditions. Now, two years into its public journey, it finds itself reevaluating its strategy again amidst clinical trial setbacks.
Prior to halting its current projects, Artiva was conducting a mid-stage basket trial encompassing multiple inflammatory diseases, including systemic sclerosis and myositis. The company had shared preliminary results from these studies earlier this year and was set to provide more data at an upcoming medical conference.